

Out of the Shadows: Normalizing the Management of UTERINE FIBROIDS and ENDOMETRIOSIS



4/21/2023



Provided by the American Academy of PAs in collaboration with The France Foundation

Supported by an educational grant from Pfizer and Myovant Sciences





Steering Committee

Breann Garbas, DHSc, PA-C

Assistant Professor, UF College of Medicine Equal Access Clinic Gainesville, FL

Nisha McKenzie, PA-C, CSC, NCMP, IF Women's Health Collective Grand Rapids, MI



Disclosures

Activity Staff Disclosures

 The planners, reviewers, editors, staff, CME committee, and other members at the AAPA and TFF who control content have no relevant financial relationships to disclose

Faculty/Steering Committee

- Breann Garbas, DHSc, PA-C, has no relevant financial relationships to disclose
- Nisha McKenzie, PA-C, CSC, NCMP, IF, has no relevant financial relationships to disclose



Periods are supposed to hurt a lot; suffering is part of having a uterus.

- A. True
- B. False



It is normal to miss school or work every month because you are bleeding too heavily.

A. True

B. False



If my patient has excessive pain or bleeding during their period, they will need a referral to OB/GYN. Within the scope of primary care, I should not attempt to manage their care. I can't begin to manage their care myself.

A. True

B. False



Endometriosis and uterine fibroids are basically the same thing in presentation and how they should be medically managed.

- A. True
- B. False



What You Will Gain Today

- A better understanding of the burden and quality of life impacts of endometriosis and uterine fibroids
- Improved ability to manage patients with these diseases, including use of GnRH agonists/antagonists
- Greater confidence when talking with patients about their menstrual cycle and its associated impacts





Endometriosis



What percentage of patients with a uterus will likely experience endometriosis during their reproductive lifetime?

- A. 5%
- B. 10%
- C. 20%
- D. 40%





Impact on Quality of Life

Overall Quality of Life

Patients with endometriosis had wellness score of 51.5, normative range 70-80 for western populations

Rush G, Misajon R. Health Care Women Int. 2018 Mar;39(3):303-321.

Racial Disparities

Black patients less likely to be diagnosed with endometriosis and offered infertility preservation counseling

Bougie O, et al. BJOG. 2019 Aug;126(9):1104-1115.



Impact on Quality of Life

Healthcare Costs

Time

• \downarrow Average of

hours/week

• ↓\$10,177.54/y

6.3 work

ear

Soliman AM, et al. J

Psychosom Obstet Gynaecol. 2017;38(4):238-248.

 Annual economic burden (direct/indirect cost) in 2009 was estimated at \$69.4 billion

Simoens S, et al. *Hum Reprod*. 2012;27(5):1292-1299.

Fertility • Patients with

endometriosis have > 2 fold higher risk of infertility

Prescott J, et al. Hum Reprod.

2016 Jul;31(7):1475-82.

Sexual Health

• 47% of patients with endometriosis had dyspareunia⁴

De Graaff AA, et al. Hum Reprod.

2013;28(10):2677-2685.

15

4/21/2023



Quality of Life



16



Diagnosis

- Medical school training in endometriosis diagnosis (laparoscopy)
- Clinical suspicion of endometriosis



Clinical Suspicion of Endometriosis

- Significant dysmenorrhea (even before menstruation)
- ✓ Heavy or painful bleeding
- ✓ Painful intercourse
- Chronic pelvic pain (> 6 months)
- ✓ Pain radiating into back or upper thighs
- Bowel or urinary pain during menses
- ✓ Upon physical exam
 - Fixed or retroverted uterus
 - Tender uterosacral ligaments
 - Uterosacral nodularity
 - Cul-de-sac nodularity



Diagnosis

Its important to diagnose early



19

4/21/2023





15

GnRH Analogs

		Agonists	Antagonist	
 Agonist versus antagonists 	Side effects	\downarrow bone mineral density and symptoms of hypogonadism	\downarrow bone mineral density and symptoms of hypogonadism	
	Approved for endometriosis	Buserelin, goserelin, and leuprolide	Elagolix, relugolix combination	
 Benefits of add-back therapy 	Method of administration	Nasal spray, Injection (daily, monthly, 3- monthly)	Oral	
	Activity	Several weeks to respond, initial flare of symptoms common	Instant response	
	Limitation of usage	Generally 6 months or less with some exceptions up to 1 year	24 months or less depending on dose and hepatic function	

22

4/21/2023



Uterine Leiomyomas (fibroids)



Prevalence

- Increases with age during reproductive years
- By age 50
 - > 80% in African American patients with a uterus
 - 70% in White patients with a uterus



Symptoms of Uterine Fibroids

- ✓ Bleeding (sometimes intermenstrual)
- ✓ Urinary frequency/urgency
- ✓ Pelvic pressure/pain
- ✓ GI tract symptoms (constipation)



Quality of Life

Medical	Missing Work	Economic	Quality of life
• Estimated primary cause of 45% of hysterectomies	 28% of patients reported missing work due to UF symptoms¹ \$4,600 estimated annual cost/patient² 	• Estimated \$34 billion healthcare dollars/year in US ²	 QoL scores similar to, or more severe than those with other chronic diseases such as diabetes or breast cancer
Wright JD, et al. <i>Obstet</i> <i>Gynecol.</i> 2013 Aug;122(2 Pt 1):233-241.	1. Borah BJ, et al. <i>Am J Obstet</i> <i>Gynecol.</i> 2013 Oct;209(4):319.e1-319.e20	2.Cardozo ER, et al. Am J Obstet Gynecol. 2012 Mar;206(3):211.e1-9.	Go VA, et al. <i>Am j obst gyn.</i> 2020 Nov 1;223(5):674-708







Case Practice

Anna is a 33-year-old patient that presents with complaints of heavy bleeding during their period. Physical exam reveals uterus enlarged to 8 weeks size and irregular shape. Ultrasound demonstrates a 3 cm concentric, solid, hypoechoic mass indicating a uterine fibroid. Anna indicates she would like to have a child in the next 5 years.



What would be the most appropriate initial treatment for Anna?

- A. Tranexamic acid
- B. NSAIDs
- C. GnRH antagonist with hormonal add-back therapy
- D. Hysterectomy



Medical Management

Medical Treatment	Bleeding	Uterine Enlargement
Gonadotropic-releasing hormone antagonists with hormonal add-back therapy	х	
Levonorgestrel-releasing intrauterine devices	х	
Contraceptive steroid hormones (limited evidence in progesterone only)	х	
Tranexamic Acid	Х	
Gonadotropic-releasing hormone agonists bridging to definitive	х	x

American College of Obstetricians and Gynecologists. Obstet Gyn. 2021 Jun 1;137(6):e100-15.



Surgical Management

- Uterine artery embolization
- Endometrial ablation (for myoma-related bleeding)
- MR guided ultrasound surgery
- Myolysis
- Myomectomy
- Hysterectomy



GnRH Antagonist Combinations: Reduction in Heavy Menstrual Bleeding Altendy A. New Eng J. Med. 2021 Feb 18:384(7):630-42.

Approved GnRH antagonist combinations:	ction in baseline)	100 90-	A neity A. ne	Trial L1	L1	
 Relugolix, estradiol, and norethindrone combination 	Reduction from base	80- 70-		73	80	
 Elagolix, estradiol, and norethindrone combination 	–	60- 50-				
 Placebo Relugolix + estradiol + norethindrone (combination) for 24 weeks Relugolix monotherapy for 12 week then relugolix combination for 12 weeks 	Percentage of Women with Heavy Menstrual Bleeding (<80ml and ≥50% decrease	40- 30- 20- 10-	19			
Difference vs. Placebo — p	No. of I percentage		127	128 55	132 61	



Do You Know?

34



When using a GnRH antagonist to treat uterine fibroids, what can be done to slow the loss of bone mineral density?

- A. Add-back therapy of estradiol and/or progestin
- B. Have patient increase physical activity
- C. Prescribe GnRH agonists in addition to antagonist
- D. There are no medical interventions to slow the side-effects of GnRH antagonists



Change in Bone Mineral Density






Case Practice

You are a primary care physician associate in a family practice. Liz is a 15-year-old patient, that comes in for a wellness check. You ask the patient how their periods are and the patient replies, "I guess ok, normal."



What should you do next?

- A. Ask no further questions regarding menstruation. This patient is too young to have serious menstrual complications.
- B. Ask no further questions regarding menstruation, even if this patient has early endometriosis. This patient should wait to move forward with intervention until they are concerned about fertility.
- C. Ask clarification questions to ascertain what "normal" means regarding menstruation and screen for menstruation irregularities. Begin treatment if discovered.
- D. Do not inquire regarding menstruation. A patient will bring up problems if they exist.
- E. Ask clarification questions to ascertain what "normal" means regarding menstruation and screen for menstruation irregularities. Immediately refer them to an OB/GYN if any questions/concerns arise.



What to Ask

- Menstrual cycle timing, duration
- Bleeding and clotting (use of pictorial bleeding chart)
- Pain and fatigue
- Pain (cycle, sex, bowel movements, and urinary)
- Infertility
- Quality of life questions (interference with daily life)

Resources:

- Endometriosis and Uterine Fibroids Screening Guide
- Endometriosis and Uterine Fibroids Provider Resource Guide



How to Ask

- Don't assume
- Address earlier bias/discrimination
 What have you been told in the past...
- Validate

4/21/2023



Empower Your Patients to Become Stakeholders in Their Own Care





Summary

- Primary care has a unique role
- If we ask the questions, they will answer
- Reach out and make connections with other providers



Post-test #1: What percentage of patients with a uterus will likely experience endometriosis during their reproductive lifetime?

- A. 5%
- B. 10%
- C. 20%
- D. 40%



Post-test #2

Anna is a 33-year-old patient that presents with complaints of heavy bleeding during their period. Physical exam reveals uterus enlarged to 8 weeks size and irregular shape. Ultrasound demonstrates a 3 cm concentric, solid, hypoechoic mass indicating a uterine fibroid. Anna indicates she would like to have a child in the next 5 years.



What would be the most appropriate initial treatment for Anna?

- A. Tranexamic acid
- B. NSAIDs
- C. GnRH antagonist with hormonal add-back therapy
- D. Hysterectomy



Post-test #3: When using a GnRH antagonist to treat uterine fibroids, what can be done to slow the loss of bone mineral density?

- A. Add-back therapy of estradiol and/or progestin
- B. Have patient increase physical activity
- C. Prescribe GnRH agonists in addition to antagonist
- D. There are no medical interventions to slow the side-effects of GnRH antagonists



Posttest #4

You are a primary care physician associate in a family practice. Liz is a 15-year-old patient, that comes in for a wellness check. You ask the patient how their periods are and the patient replies, "I guess ok, normal."



What should you do next?

- A. Ask no further questions regarding menstruation. This patient is too young to have serious menstrual complications.
- B. Ask no further questions regarding menstruation, even if this patient has early endometriosis. This patient should wait to move forward with intervention until they are concerned about fertility.
- C. Ask clarification questions to ascertain what "normal" means regarding menstruation and screen for menstruation irregularities. Begin treatment if discovered.
- D. Do not inquire regarding menstruation. A patient will bring up problems if they exist.
- E. Ask clarification questions to ascertain what "normal" means regarding menstruation and screen for menstruation irregularities. Immediately refer them to an OB/GYN if any questions/concerns arise.



Questions?